Carola Berking

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7290639/publications.pdf Version: 2024-02-01

202 papers	11,227 citations	41344 49 h-index	³⁴⁹⁸⁶ 98 g-index
231	231	231	16795
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Melanoma. Lancet, The, 2018, 392, 971-984.	13.7	1,016
2	The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 2014, 4, 94-109.	9.4	782
3	Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 757-767.	10.7	562
4	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	7.0	480
5	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Reviews, 2016, 45, 7-18.	7.7	354
6	5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	30.7	353
7	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells. Journal of Clinical Investigation, 2009, 119, 2399-411.	8.2	322
8	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncology, The, 2020, 21, 294-305.	10.7	304
9	Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. European Journal of Cancer, 2019, 113, 47-54.	2.8	300
10	Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review. Journal of Medical Internet Research, 2018, 20, e11936.	4.3	277
11	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 2015, 51, 2792-2799.	2.8	269
12	Deep neural networks are superior to dermatologists in melanoma image classification. European Journal of Cancer, 2019, 119, 11-17.	2.8	212
13	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	1.6	207
14	Superior skin cancer classification by the combination of human and artificial intelligence. European Journal of Cancer, 2019, 120, 114-121.	2.8	197
15	A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. European Journal of Cancer, 2019, 111, 148-154.	2.8	197
16	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2020, 395, 1558-1568.	13.7	188
17	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. European Journal of Cancer, 2017, 82, 56-65.	2.8	162
18	Pathologist-level classification of histopathological melanoma images with deep neural networks. European Journal of Cancer, 2019, 115, 79-83.	2.8	156

#	Article	IF	CITATIONS
19	SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 2021, 80, 1312-1316.	0.9	154
20	The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study. British Journal of Dermatology, 2015, 173, 428-435.	1.5	138
21	Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. European Journal of Cancer, 2019, 119, 57-65.	2.8	134
22	Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. European Journal of Cancer, 2021, 156, 202-216.	2.8	115
23	Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer, 2017, 17, 536.	2.6	113
24	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
25	Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. European Journal of Cancer, 2019, 111, 30-37.	2.8	104
26	CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis. Annals of Neurology, 2016, 80, 294-300.	5.3	94
27	Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation. Melanoma Research, 2000, 10, 303-312.	1.2	90
28	Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Cancer Treatment Reviews, 2017, 60, 44-52.	7.7	90
29	Induction of Melanoma Phenotypes in Human Skin by Growth Factors and Ultraviolet B. Cancer Research, 2004, 64, 807-811.	0.9	82
30	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 2020, 11, 3774.	12.8	78
31	The Efficacy of Photodynamic Therapy in Actinic Cheilitis of the Lower Lip: A Prospective Study of 15 Patients. Dermatologic Surgery, 2007, 33, 825-830.	0.8	77
32	A nine-gene signature predicting clinical outcome in cutaneous melanoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 249-258.	2.5	77
33	Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. European Journal of Cancer, 2017, 81, 36-44.	2.8	76
34	Differential expression of melanoma-associated growth factors in keratinocytes and fibroblasts by ultraviolet A and ultraviolet B radiation. British Journal of Dermatology, 2005, 153, 733-739.	1.5	75
35	A randomized, doublea€blind, phase <scp>III</scp> , multicentre study to evaluate the safety and efficacy of <scp>BF</scp> â€200 <scp>ALA</scp> (Ameluz [®]) vs. placebo in the fieldâ€directed treatment of mildâ€toâ€moderate actinic keratosis with photodynamic therapy (PDT) when using the <scp>BF</scp> â€Rhodo <scp>LED</scp> [®] lamp. British Journal of Dermatology, 2016, 175,	1.5	74
36	Basic Fibroblast Growth Factor and Ultraviolet B Transform Melanocytes in Human Skin. American Journal of Pathology, 2001, 158, 943-953.	3.8	72

#	Article	IF	CITATIONS
37	Morphology of basal cell carcinoma in high definition optical coherence tomography: enâ€face and slice imaging mode, and comparison with histology. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e97-104.	2.4	71
38	SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity. Journal of Investigative Dermatology, 2014, 134, 2212-2220.	0.7	70
39	Basal Cell Carcinoma. Deutsches Ärzteblatt International, 2014, 111, 389-95.	0.9	64
40	Photocarcinogenesis in human adult skin grafts. Carcinogenesis, 2002, 23, 181-187.	2.8	63
41	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunology, Immunotherapy, 2016, 65, 951-959.	4.2	62
42	The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Oncogene, 2017, 36, 5110-5121.	5.9	59
43	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. European Journal of Cancer, 2018, 98, 10-16.	2.8	57
44	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and qualityâ€ofâ€care indicators. JDDG - Journal of the German Society of Dermatology, 2020, 18, 275-294.	0.8	57
45	The Role of Immune Checkpoint Blockade in Uveal Melanoma. International Journal of Molecular Sciences, 2020, 21, 879.	4.1	57
46	Nestin and SOX9 and SOX10 transcription factors are coexpressed in melanoma. Experimental Dermatology, 2010, 19, e89-94.	2.9	56
47	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine, 2015, 13, 351.	4.4	56
48	Photodynamic Therapy of Necrobiosis Lipoidica – A Multicenter Study of 18 Patients. Dermatology, 2009, 218, 136-139.	2.1	55
49	Erythema nodosumâ€like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1797-1806.	2.4	55
50	Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. Annals of Oncology, 2017, 28, 3104-3106.	1.2	53
51	Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFRâ€1, câ€kit) in nevi and melanoma. Journal of Cutaneous Pathology, 2007, 34, 7-14.	1.3	52
52	How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. European Journal of Cancer, 2018, 103, 41-51.	2.8	50
53	Actinic keratosis in the <i>en-face</i> and slice imaging mode of high-definition optical coherence tomography and comparison with histology. British Journal of Dermatology, 2013, 168, 120-128.	1.5	48
54	Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 2014, 25, 747-753.	1.2	47

#	Article	IF	CITATIONS
55	Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: Pseudocysts as a sign of tumor regression. Journal of the American Academy of Dermatology, 2014, 71, 725-730.	1.2	47
56	High-definition optical coherence tomography of melanocytic skin lesions. Journal of Biophotonics, 2015, 8, 681-686.	2.3	46
57	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
58	Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 581-587.	1.2	45
59	Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing. Journal of Medical Internet Research, 2018, 20, e11871.	4.3	44
60	SOX9 and SOX10 but Not BRN2 Are Required for Nestin Expression in Human Melanoma Cells. Journal of Investigative Dermatology, 2009, 129, 945-953.	0.7	43
61	Explainable artificial intelligenceÂin skin cancer recognition: A systematic review. European Journal of Cancer, 2022, 167, 54-69.	2.8	42
62	Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53. Cell Death and Differentiation, 2007, 14, 818-829.	11.2	40
63	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	2.8	40
64	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, followâ€up, prevention and occupational disease. JDDG - Journal of the German Society of Dermatology, 2020, 18, 400-413.	0.8	39
65	Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2019, 80, 947-956.	1.2	38
66	Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside. Experimental Dermatology, 2016, 25, 831-838.	2.9	37
67	Tumor markers in peripheral blood of patients with malignant melanoma: Multimarker RT-PCR versus a luminoimmunometric assay for S-100. Archives of Dermatological Research, 1999, 291, 479-484.	1.9	35
68	Local interventions for actinic keratosis in organ transplant recipients: a systematic review. British Journal of Dermatology, 2019, 180, 43-50.	1.5	35
69	Kinetics of human myeloid-derived suppressor cells after blood draw. Journal of Translational Medicine, 2016, 14, 2.	4.4	34
70	Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 2018, 118, 785-792.	6.4	34
71	A benchmark for neural network robustness in skin cancer classification. European Journal of Cancer, 2021, 155, 191-199.	2.8	34
72	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology, 2022, 40, 3741-3749.	1.6	33

#	Article	IF	CITATIONS
73	The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. EMBO Molecular Medicine, 2013, 5, 919-934.	6.9	31
74	The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. Oncotarget, 2018, 9, 34336-34346.	1.8	31
75	Identification and characterization of 20 immunocompetent patients with simultaneous varicella zoster and herpes simplex virus infection. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 722-728.	2.4	29
76	Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. British Journal of Dermatology, 2015, 172, 816-818.	1.5	29
77	MSX1-Induced Neural Crest-Like Reprogramming Promotes MelanomaÂProgression. Journal of Investigative Dermatology, 2018, 138, 141-149.	0.7	29
78	The Value of Total Body Photography for the Early Detection of Melanoma: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 1726.	2.6	28
79	Photodynamic Therapy for Granuloma Annulare: More than a Shot in the Dark. Dermatology, 2008, 217, 329-332.	2.1	27
80	Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology, 2011, 22, 1667-1674.	1.2	27
81	Immunofluorescence and confocal microscopy for exâ€vivo diagnosis of melanocytic and nonâ€melanocytic skin tumors: A pilot study. Journal of Biophotonics, 2018, 11, e201700211.	2.3	26
82	Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 863-873.	2.4	26
83	Allele frequencies of BRAF <i>V600</i> mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget, 2015, 6, 37895-37905.	1.8	26
84	Risk factors for early-onset basal cell carcinoma in a German institution. European Journal of Dermatology, 2011, 21, 705-709.	0.6	25
85	Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and metaâ€analysis. British Journal of Dermatology, 2019, 180, 740-748.	1.5	25
86	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study Journal of Clinical Oncology, 2018, 36, 9527-9527.	1.6	25
87	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. JAMA Dermatology, 2021, 157, 1066.	4.1	24
88	A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging. JNCI Cancer Spectrum, 2018, 2, pky032.	2.9	23
89	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. International Journal of Molecular Sciences, 2020, 21, 9300.	4.1	23
90	The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion. Pigment Cell and Melanoma Research, 2019, 32, 424-434.	3.3	22

#	Article	IF	CITATIONS
91	Daylight PDT with MAL – current data and practical recommendations of an expert panel. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1240-1249.	0.8	21
92	In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins. Cell Death and Disease, 2015, 6, e1996-e1996.	6.3	20
93	POU transcription factors in melanocytes and melanoma. European Journal of Cell Biology, 2014, 93, 55-60.	3.6	19
94	Low baseline levels of <scp>NK</scp> cells may predict a positive response to ipilimumab in melanoma therapy. Experimental Dermatology, 2017, 26, 622-629.	2.9	19
95	How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. International Journal of Molecular Sciences, 2021, 22, 5761.	4.1	19
96	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. Journal of Medical Internet Research, 2018, 20, e10976.	4.3	19
97	Patient Attitudes and Their Awareness Towards Skin Cancer–Related Apps: Cross-Sectional Survey. JMIR MHealth and UHealth, 2019, 7, e13844.	3.7	19
98	Combination therapy of melanoma using kinase inhibitors. Current Opinion in Oncology, 2015, 27, 134-140.	2.4	18
99	The more the better? An appraisal of combination therapies for actinic keratosis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 727-732.	2.4	18
100	Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma. Cancers, 2020, 12, 2516.	3.7	18
101	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers, 2021, 13, 3359.	3.7	18
102	Morphologic features of basal cell carcinoma using the enâ€face mode in frequency domain optical coherence tomography. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1919-1925.	2.4	17
103	c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. European Journal of Cancer, 2021, 157, 348-357.	2.8	17
104	Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis. JMIR Cancer, 2018, 4, e10676.	2.4	17
105	Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node Journal of Clinical Oncology, 2018, 36, 9501-9501.	1.6	16
106	A disease networkâ€based deep learning approach for characterizing melanoma. International Journal of Cancer, 2022, 150, 1029-1044.	5.1	16
107	Nonâ€invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques. Journal of Biophotonics. 2019. 12. e201800391.	2.3	15
108	Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1079-1088.	2.5	15

#	Article	IF	CITATIONS
109	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	2.8	15
110	Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. Deutsches Ärzteblatt International, 2019, 116, 616-626.	0.9	15
111	Indications and Use of Isotretinoin in Facial Plastic Surgery. Facial Plastic Surgery, 2018, 34, 075-081.	0.9	14
112	Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment. Medical Oncology, 2018, 35, 135.	2.5	14
113	Unmet information needs of patients with melanoma in Germany. Melanoma Research, 2019, 29, 196-204.	1.2	14
114	Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients. Journal of Cancer Education, 2019, 34, 760-767.	1.3	14
115	Comparison of guidelines for the management of patients with highâ€risk and advanced cutaneous squamous cell carcinoma – a systematic review. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 25-32.	2.4	14
116	Assessment of the Quality, Understandability, and Reliability of YouTube Videos as a Source of Information on Basal Cell Carcinoma: Web-Based Analysis. JMIR Cancer, 2022, 8, e29581.	2.4	14
117	Optical coherence tomography imaging of basal cell carcinoma undergoing photodynamic therapy: A pilot study. Photodiagnosis and Photodynamic Therapy, 2017, 18, 133-137.	2.6	13
118	Informationâ€seeking and use of information resources among melanoma patients of German skin cancer centers. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1093-1101.	0.8	13
119	A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources. European Journal of Dermatology, 2014, 24, 335-341.	0.6	12
120	Transient memory impairment and transient global amnesia induced by photodynamic therapy. British Journal of Dermatology, 2015, 173, 1258-1262.	1.5	11
121	A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. Journal of Clinical Medicine, 2020, 9, 2253.	2.4	11
122	The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments. Cancers, 2020, 12, 1613.	3.7	11
123	Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 2022, 86, 1116-1119.	1.2	11
124	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
125	Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: Results from a systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2020, 82, 515-519.	1.2	10
126	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group. European Journal of Cancer, 2021, 149, 1-10.	2.8	10

#	Article	IF	CITATIONS
127	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under realâ€world conditions in Germany – The nonâ€interventional study NIELS. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1678-1685.	2.4	10
128	Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy. ESMO Open, 2021, 6, 100248.	4.5	10
129	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 2021, 11, 765608.	2.8	10
130	Clinical determinants of long-term survival in metastatic uveal melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 1467-1477.	4.2	10
131	A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity inÂMelanoma. Journal of Investigative Dermatology, 2016, 136, 2475-2484.	0.7	9
132	BILATERAL VISUAL FIELD DEFECTS IN A PATIENT TREATED WITH THE MEK AND BRAF INHIBITORS TRAMETINIB AND DABRAFENIB FOR MELANOMA OF UNKNOWN ORIGIN. Retinal Cases and Brief Reports, 2019, 13, 215-219.	0.6	9
133	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. , 2020, 8, e000395.		9
134	German YouTubeâ,,¢ videos as a source of information on cutaneous melanoma: a critical appraisal. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e642-e644.	2.4	9
135	Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. Journal of Investigative Dermatology, 2021, 141, 345-354.e8.	0.7	9
136	Chemical peelings for the treatment of actinic keratosis: a systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 641-649.	2.4	9
137	Safety of topical interventions for the treatment of actinic keratosis. Expert Opinion on Drug Safety, 2021, 20, 801-814.	2.4	9
138	Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. BMJ Open, 2021, 11, e049208.	1.9	9
139	A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma. Frontiers in Immunology, 2022, 13, 785231.	4.8	9
140	Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against <scp>SARS</scp> – <scp>CoV</scp> â€2 in an Unvaccinated Cohort. Arthritis and Rheumatology, 2022, 74, 783-790.	5.6	9
141	Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial Journal of Clinical Oncology, 2015, 33, LBA9002-LBA9002.	1.6	8
142	BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation. International Journal of Molecular Sciences, 2021, 22, 11951.	4.1	8
143	Subluminescence photodynamic therapy of recalcitrant foot warts. British Journal of Dermatology, 2015, 172, 813-816.	1.5	7
144	Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System. Journal of Investigative Dermatology, 2022, 142, 2149-2158.e10.	0.7	7

#	Article	IF	CITATIONS
145	Long-term efficacy of interventions for actinic keratosis: protocol for a systematic review and network meta-analysis. Systematic Reviews, 2019, 8, 237.	5.3	6
146	Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. Photodermatology Photoimmunology and Photomedicine, 2020, 36, 126-134.	1.5	6
147	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers, 2022, 14, 518.	3.7	6
148	Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials. Scientific Reports, 2022, 12, 5884.	3.3	6
149	Patient Attitude towards Videodermatoscopy for the Detection of Skin Cancer: A Cross-Sectional Study. Oncology Research and Treatment, 2019, 42, 319-325.	1.2	5
150	Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of the existing evidence. British Journal of Dermatology, 2020, 183, 380-382.	1.5	5
151	A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis. Current Oncology, 2021, 28, 950-960.	2.2	5
152	Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors. Journal of Immunotherapy, 2021, 44, 193-197.	2.4	5
153	A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells. International Journal of Molecular Sciences, 2021, 22, 10227.	4.1	5
154	How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results. Journal of Clinical Medicine, 2021, 10, 4736.	2.4	5
155	Immune Checkpoint Inhibitor-induced Bilateral Vestibulopathy. Journal of Immunotherapy, 2021, 44, 114-117.	2.4	5
156	Patient Perception of Mobile Phone Apps for the Care and Prevention of Sexually Transmitted Diseases: Cross-Sectional Study. JMIR MHealth and UHealth, 2020, 8, e16517.	3.7	5
157	HDAC2 Is Involved in the Regulation of BRN3A in Melanocytes and Melanoma. International Journal of Molecular Sciences, 2022, 23, 849.	4.1	5
158	Intravascular Large B-Cell Lymphoma: A Review with a Focus on the Prognostic Value of Skin Involvement. Current Oncology, 2022, 29, 2909-2919.	2.2	5
159	Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences. JDDG - Journal of the German Society of Dermatology, 2019, 17, 652-654.	0.8	4
160	Successful Treatment of Genital Warts with Ingenol Mebutate Monitored with Optical Coherence Tomography and Reflectance Confocal Microscopy. Annals of Dermatology, 2019, 31, 434.	0.9	4
161	Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma. European Journal of Cancer, 2022, 170, 42-53.	2.8	4
162	Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab. Cancer Immunology, Immunotherapy, 2017, 66, 1377-1378.	4.2	3

#	Article	IF	CITATIONS
163	Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set. Trials, 2019, 20, 589.	1.6	3
164	Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors. Facial Plastic Surgery, 2020, 36, 249-254.	0.9	3
165	Monitoring skin metastases during immuno―and targeted therapy using totalâ€body 3D photography. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e61-e63.	2.4	3
166	Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2021, 19, 608-610.	0.8	3
167	Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion. Journal of Immunotherapy, 2021, 44, 71-75.	2.4	3
168	Open-label, multicenter safety study of vemurafenib in patients with <i>BRAF^{V600}</i> mutation–positive metastatic melanoma Journal of Clinical Oncology, 2013, 31, 9046-9046.	1.6	3
169	Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial Journal of Clinical Oncology, 2015, 33, LBA9002-LBA9002.	1.6	3
170	Facial-Aging Mobile Apps for Smoking Prevention in Secondary Schools in Brazil: Appearance-Focused Interventional Study. JMIR Public Health and Surveillance, 2018, 4, e10234.	2.6	3
171	Implications of the COVID-19 Pandemic for the Development and Update of Clinical Practice Guidelines: Viewpoint. Journal of Medical Internet Research, 2020, 22, e20064.	4.3	3
172	Cytodiagnosis of erosive melanoma and basal cell carcinoma of the skin using cutaneous tissue smear. Clinical and Experimental Dermatology, 2013, 38, 251-261.	1.3	2
173	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology, 2021, 147, 1763-1771.	2.5	2
174	Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients. Journal of Immunotherapy, 2021, 44, 239-241.	2.4	2
175	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups Journal of Clinical Oncology, 2014, 32, 9031-9031.	1.6	2
176	Validation, in silico and in vitro, of a gene-signature based risk score in cutaneous melanoma Journal of Clinical Oncology, 2017, 35, 9560-9560.	1.6	2
177	The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology. European Journal of Dermatology, 2020, 30, 757-758.	0.6	2
178	Increasing Participation Rates in Germany's Skin Cancer Screening Program (HELIOS): Protocol for a Mixed Methods Study. JMIR Research Protocols, 2021, 10, e31860.	1.0	2
179	Neue Entwicklungen in der Fluoreszenzdiagnostik. JDDG - Journal of the German Society of Dermatology, 2011, 9, 368-373.	0.8	1
180	Cash is king: the balance of costs and effectiveness of treatments for actinic keratosis. British Journal of Dermatology, 2020, 183, 612-612.	1.5	1

#	Article	IF	CITATIONS
181	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. European Journal of Cancer, 2021, 143, 43-45.	2.8	1
182	The genetic landscape of clinical resistance to RAF inhibition in melanoma Journal of Clinical Oncology, 2013, 31, 11009-11009.	1.6	1
183	NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts Journal of Clinical Oncology, 2017, 35, e21035-e21035.	1.6	1
184	Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial Journal of Clinical Oncology, 2014, 32, 9071-9071.	1.6	1
185	UVâ€Schutzbündnis verabschiedet ein neues Grundsatzpapier zur Verhänispräention: Vorbeugung gesundheitlicher Schäen der Sonne – Verhänispräention in der Stadt und auf dem Land. JDDG - Journal of the German Society of Dermatology, 2017, 15, 687-687.	0.8	0
186	Targeted Therapy of Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 2018, 19, S86.	0.8	0
187	Photodynamic therapy †to go' – a strengths, weaknesses, opportunities and threats analysis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e447-e449.	2.4	0
188	Conceptual, statistical and clinical interpretation of results from: Cryosurgery combined with topical interventions for actinic keratosis: reply from the authors. British Journal of Dermatology, 2019, 181, 424-425.	1.5	0
189	The value of convolutional neural networks in the diagnosis of melanoma simulators. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1134-1135.	2.4	0
190	Experiences of In-Patients with Skin Cancer in a German University Hospital Setting: A Cross-Sectional Survey. Patient Preference and Adherence, 2021, Volume 15, 41-48.	1.8	0
191	One set to collect them all? The development of a core domain set for mediumâ€ŧoâ€giant congenital melanocytic naevi. British Journal of Dermatology, 2021, 185, 247-248.	1.5	0
192	Onkologische Systemtherapie bis zum bitteren Ende?. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1259-1260.	0.8	0
193	Another step on the road towards standardized outcome reporting for congenital melanocytic naevi: one more to go!. British Journal of Dermatology, 2021, 185, 881-882.	1.5	0
194	30Âyears German Dermatologic Cooperative Oncology GroupÂ(DeCOG). JDDG - Journal of the German Society of Dermatology, 2021, 19, 1682-1697.	0.8	0
195	30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO). JDDG - Journal of the German Society of Dermatology, 2021, 19, 1682-1697.	0.8	0
196	Aktuelles zur photodynamischen Therapie und Fluoreszenzdiagnostik. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 565-581.	0.0	0
197	Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial Journal of Clinical Oncology, 2015, 33, e20080-e20080.	1.6	0
198	Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing Journal of Clinical Oncology, 2015, 33, 11061-11061.	1.6	0

#	Article	IF	CITATIONS
199	Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) Journal of Clinical Oncology, 2016, 34, 9558-9558.	1.6	Ο
200	Tebentafusp als neuartige Immuntherapie zeigt einen Überlebensvorteil beim metastasierten Uveamelanom und wird bereits in Deutschland eingesetzt. JDDG - Journal of the German Society of Dermatology, 2022, 20, 381-383.	0.8	0
201	Efficacy of Therapies for Actinic Keratosis—Reply. JAMA Dermatology, 2022, , .	4.1	О
202	The need for regular training in skin cancer screening: a crossâ€sectional study among general practitioners in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36,	2.4	0